posted on 2023-07-07, 04:05authored byC Tsui, L Kretschmer, S Rapelius, SS Gabriel, David Chisanga, K Knöpper, DT Utzschneider, S Nüssing, Yang Liao, T Mason, SV Torres, SA Wilcox, K Kanev, S Jarosch, J Leube, SL Nutt, D Zehn, IA Parish, W Kastenmüller, Wei Shi, VR Buchholz, A Kallies
<p>CD8+ T cells that respond to chronic viral infections or cancer are characterized by the expression of inhibitory receptors such as programmed cell death protein 1 (PD-1) and by the impaired production of cytokines. This state of restrained functionality—which is referred to as T cell exhaustion1,2—is maintained by precursors of exhausted T (TPEX) cells that express the transcription factor T cell factor 1 (TCF1), self-renew and give rise to TCF1− exhausted effector T cells 3–6. Here we show that the long-term proliferative potential, multipotency and repopulation capacity of exhausted T cells during chronic infection are selectively preserved in a small population of transcriptionally distinct CD62L+ TPEX cells. The transcription factor MYB is not only essential for the development of CD62L+ TPEX cells and maintenance of the antiviral CD8+ T cell response, but also induces functional exhaustion and thereby prevents lethal immunopathology. Furthermore, the proliferative burst in response to PD-1 checkpoint inhibition originates exclusively from CD62L+ TPEX cells and depends on MYB. Our findings identify CD62L+ TPEX cells as a stem-like population that is central to the maintenance of long-term antiviral immunity and responsiveness to immunotherapy. Moreover, they show that MYB is a transcriptional orchestrator of two fundamental aspects of exhausted T cell responses: the downregulation of effector function and the long-term preservation of self-renewal capacity.</p>
Funding
This work was supported by the National Health and Medical Research Council of Australia (NHMRC) Research Fellowship (to A.K.) and Ideas Grants (APP2004333 to A.K. and C.T.; APP2001719 to I.A.P.); the European Research Council (starting grant 949719 SCIMAP to V.R.B.); the Else Kroner-Fresenius-Stiftung (EKFS 2019_A91 to V.R.B.); the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation; SFB-TRR 338/1 2021-452881907, SFB 1054-210592381 to V.R.B.); and the Deutsche Krebshilfe (DKH 70113918 to V.R.B).